Reneo Pharmaceuticals, Inc.

Equities

RPHM

US75974E1038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
1.52 ^USD	+2.70%		+3.40%	-5.00%

07-01	Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000E Value Index	CI
07-01	Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2000 Value Index	CI

Tranche Update on Reneo Pharmaceuticals, Inc.'s Equity Buyback Plan announced on October 30, 2023.

March 28, 2024 at 04:02 pm

From October 30, 2023 to October 30, 2023, the company has repurchased 576,443 shares, for $4.4 million. With this, the company has completed the repurchase of 576,443 shares, for $4.4 million under the buyback announced on October 30, 2023.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	VTV THERAPEUTICS INC.	23.75 USD	+5.51%	+31.22%	57.78M
	RENEO PHARMACEUTICALS, INC.	1.52 USD	+2.70%	+3.40%	50.8M

Latest news about Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000E Value Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2000 Value Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2000 Growth Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000 Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2000 Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000 Value Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000 Growth Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Value Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2000 Dynamic Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Microcap Growth Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000E Growth Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Comp Value Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Completeness Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 3000E Index	06-30	CI
Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Growth Index	06-30	CI
Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing	05-16	MT
Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise	05-13	MT
OnKure, Inc. entered into an agreement to acquire Reneo Pharmaceuticals, Inc.	05-12	CI
Reneo Pharmaceuticals, Inc. announced that it expects to receive $65 million in funding from OnKure, Inc., RADIATE MERGER SUB II, LLC, Radiate Merger Sub I, Inc	05-09	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Tranche Update on Reneo Pharmaceuticals, Inc.'s Equity Buyback Plan announced on October 30, 2023.	03-28	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ

Chart Reneo Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.52 USD

Average target price

1.5 USD

Spread / Average Target

-1.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RENEO PHARMACEUTICALS, INC.	-5.00%	50.8M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.26%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research